This Sources Sought opportunity from Department Of Defense was posted on June 12, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Contact Activation Pathway Function Blocking Antibody AB023

Closed

HT9426-26-RFI-WS03Federal

Submission Closed06/18/2026, 02:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714

New

Federal

Human Hindbrain Organoid Functional Assay Services.

Solicitation # RFQ_CDR-2026-135968

The U.S. Food and Drug Administration's Center for Drug Evaluation and Research intends to award a sole-source, firm-fixed-price purchase order to OrganoTherapeutics SARL for human induced pluripotent stem cell (iPSC)-derived hindbrain organoid functional assay services. The project aims to support in vitro research evaluating drug-induced effects on respiratory-relevant neural circuits over an eighteen-month period of performance. The scope of work is divided into two primary components: the provision of human hindbrain organoids and associated culture materials through twelve scheduled deliveries to the FDA White Oak Campus, and the performance of functional characterization services at the contractor's laboratory. Functional characterization will utilize three-dimensional multi-electrode array (3D MEA) technology to assess electrophysiological responses to FDA-identified drug and reversal-agent combinations. Deliverables include the delivery of 96 organoids in the first shipment followed by 48 organoids in subsequent deliveries, as well as raw data, analyzed data, analysis files, and comprehensive study reports. This acquisition is conducted as a commercial service under FAR Part 12, with the government restricting competition based on market research identifying OrganoTherapeutics SARL as the only source capable of meeting the complete requirement for both the specific organoid products and the associated functional assay services.

FDA Office Of Acq Grant Svcs

POSTED

DEADLINE

Hypoxia Chamber Services

Solicitation # 80JSC026Q0008

NASA Johnson Space Center is soliciting combined synopsis and request for quotations under solicitation 80JSC026Q0008 for Hypoxia Chamber Services to support the Artemis Program. The objective is to investigate the physiological, cognitive, and clinical effects of mild hypobaric hypoxia through two 7-day test protocols involving continuous habitation for six subjects at air equivalent altitudes of 7,000 and 9,500 feet. The scope of work encompasses the provision of infrastructure, personnel, training, materials, and operational support. The contract is structured as a firm fixed price agreement with a base period from September 15, 2026, to September 30, 2027, and multiple option periods extending through March 1, 2030. The acquisition is open to all responsible sources under NAICS code 541714, with a size standard of 1,000 employees. Evaluation is based on a trade-off process where technical acceptability and past performance are significantly more important than price. Proposals must be submitted via email to the designated points of contact by October 1, 2026, following an extension granted in Amendment 0004. Key requirements include the submission of FAR 52.212-3 representations and certifications and adherence to specific submission criteria regarding team qualifications and risk assessment. The contract also incorporates strict guidelines regarding the protection of sensitive information and restrictions on funding activities with China.

NASA Johnson Space Center

POSTED

DEADLINE

Hypobaric Chamber Pilot Studies

Solicitation # 80JSC026Q0006

NASA Johnson Space Center is soliciting quotes under solicitation 80JSC026Q0006 for pilot hypobaric chamber testing facilities to support decompression sickness research. The primary objective is to validate non-NASA resources for safe prebreathe procedures and extravehicular activity to support Artemis mission planning. The base requirement consists of three test days, with a minimum of two subjects per day, collecting and recording data according to research protocols. The contract also includes six optional work items, including additional test days, inflight-like treatment preparation, elevated metabolic rate testing, pharmaceutical-enhanced prebreathe, and body temperature studies. The base period of performance runs from September 1, 2026, to September 30, 2027, with various option periods extending through March or September 2029. This is a small business set-aside acquisition under NAICS code 541714. Awards will be made based on a trade-off analysis where technical acceptability and past performance are significantly more important than price. Technical evaluation focuses on facility capabilities, medical support, team expertise, and the proposed schedule for subject throughput. Offerors must provide a price quotation using the provided pricing sheet, and quotes must remain valid for at least 90 days. Following several amendments, the final deadline for the submission of offers is October 1, 2026, at 1:00 p.m. Central Time. All submissions must be sent electronically to the designated points of contact.

NASA Johnson Space Center

POSTED

DEADLINE

Undiagnosed Diseases Network (UDN) Diagnostic Research Innovation CenterThe National Institutes of Health, through the NINDS, is forecasting the establishment of a Diagnostic Research Innovation Center to support the next phase of the Undiagnosed Diseases Network. This center will operate as part of a broader ecosystem including the Clinical and Data Coordinating Center, Networks of Diagnostic Excellence, and the NIH Undiagnosed Diseases Program. The primary objective of the center is to advance innovative diagnostic tools and strategies for both genomic and non-genomic conditions, which includes the systematic re-evaluation of unsolved cases from previous network phases. The center will focus on generating and testing diagnostic hypotheses by utilizing advanced sequencing, multi-omics, and gene function studies in animal and human in vitro models. By collaborating with various network stakeholders, the center aims to identify novel disease-associated genes, genomic variants, and new syndromes. This initiative seeks an integrated center featuring investigators with a history of scientific synergy and collaboration. While this is currently a forecast to allow potential applicants time to plan and establish partnerships, formal applications are not yet being solicited.

National Institutes Of Health

POSTED

DEADLINE

study entitled “Malaria and vector borne disease surveillance in the Colombia/Venezuela border”

Solicitation # ERP_1301373256

The Naval Medical Research Unit South in Lima, Peru, is seeking a provider to conduct a study focused on malaria and vector borne disease surveillance along the Colombia and Venezuela border. While the government has identified the Administrators of Tulane Educational Fund as the only vendor currently capable of supporting the entire requirement, they are issuing this notice to identify other capable sources before proceeding with a sole source award under FAR 13.106-1(b)(i). Interested parties must submit a capability statement including technical, management, and cost data to Genaro Vasquez via email by 12:00 PM local time on September 18, 2026. Submissions must be in Microsoft Word or PDF format, not exceed five pages, and use the subject line ERP_1301373256. The government will use these submissions to determine whether to pursue a competitive procurement or move forward with the intended sole source contract.

Naval Medical Research Center

POSTED

DEADLINE

Cryo-Electron Microscopy (Cryo-EM) Services

Solicitation # 75N98026Q01177

The National Institutes of Health Olao, under the Department of Health and Human Services, is seeking providers for Cryo-Electron Microscopy (Cryo-EM) Services under solicitation number 75N98026Q01177. This combined contract opportunity is categorized under NAICS code 541714 and is managed by the office located in Bethesda, Maryland. Interested parties must submit their responses by the deadline of September 16, 2026, at 6:00 PM. The primary point of contact for this procurement is Roxane S. Burkett.

National Institutes Of Health Olao

POSTED

DEADLINE

TIDAL: Target-Induced Droplet Assembly of Ligands

Solicitation # S-197478

Developed by Los Alamos National Laboratory, TIDAL (Target-Induced Droplet Assembly of Ligands) is a programmable protein-only material that utilizes nanobodies fused with encapsulation peptides to create dynamic, liquid-like droplets through phase separation. This technology allows for the precise concentration of binders upon encountering a target ligand, enabling a versatile platform for resin-free protein purification, high-sensitivity diagnostics, and the creation of slow-release drug depots. It can also function intracellularly to sequester and neutralize harmful proteins associated with viral infections or cancer. The technology is currently at TRL 3 with a patent pending and is available for exclusive or non-exclusive licensing through the Department of Energy contractor, Triad. Key market applications span biopharmaceutical manufacturing, therapeutics, and biotechnology. Interested parties can contact Caleb Ledgerwood or Lindsay Augustyn via the provided licensing email to explore commercial partnerships for this innovation.

Triad - DOE Contractor

POSTED

DEADLINE

Master Protocol Development & Adaptive Design

POSTED

DEADLINE

Phase I/II Clinical Trial Management & Execution

POSTED

DEADLINE

Chemical, Biological, Radiological and Nuclear Advance Defense Enabling Network and Clinical Capability (CADENCC)

Solicitation # W911SR-26-9-CADENCC

The Department of the Army, through the Army Contracting Command Edgewood Contracting Division and the Joint Project Lead Enabling Technologies, is seeking preproposals for the Chemical, Biological, Radiological and Nuclear Advance Defense Enabling Network and Clinical Capability project. This initiative aims to accelerate clinical trial startups for CBRN defense readiness by implementing Master Protocols, utilizing innovative technologies for decentralized trial operations, and establishing a pre-positioned clinical trial site network. The project will primarily focus on Phase I and Phase II clinical trials for early treatment products, post-exposure prophylaxis, and pre-exposure prophylaxis, including those under the Animal Rule. This opportunity is issued under 10 USC 4022 Other Transaction Authority for a prototype project, with the potential for non-competitive follow-on production contracts for successful performers. Preproposals are due by 1500 hours on September 17, 2026, and must be limited to 10 pages. Evaluation will be based on technical merit, military relevance, technology readiness level 4 or above, regulatory compliance with FDA guidelines, and best overall value. Prospective awardees must be registered in the System for Award Management database.

POSTED

DEADLINE

Rapid Prototyping and Hardware EngineerThis subcontract with the Defense Advanced Research Projects Agency focuses on the design, development, and manufacturing of next-generation military hardware for prime contractors. The scope of work involves executing rapid prototyping and scalable deployment strategies through the use of additive manufacturing and high-fidelity testing environments. Key deliverables include hardware prototypes, technical design documents, and comprehensive manufacturing scalability plans. The project requires strict adherence to NIST SP 800-171 and DoDI 8582.01 standards to ensure the protection of Controlled Unclassified Information. Classified under NAICS code 541714, the opportunity was posted on September 3, 2026, with a response deadline of June 1, 2027.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

Solicitation # DARPA-SN-26-121

The Defense Advanced Research Projects Agency's Biological Technologies Office is hosting a Proposers Day for the High-throughput Unmasking of Biological Interactomes with Binding Landscape Emulators program. This event is scheduled for September 25, 2026, from 12:00 PM to 5:00 PM Eastern Time at the SPA Arlington Research Collaboration Center in Arlington, Virginia. While a hybrid option is available for attendees, all presenters are required to be present in person. Interested parties must complete advance registration by the response deadline of September 18, 2026. This special notice, identified by solicitation number DARPA-SN-26-121 and NAICS code 541714, serves as a preparatory step for a planned Program Announcement. Primary coordination for the event is managed by Dr. Abhishek Singharoy.

Defense Advanced Research Projects Agcy

POSTED

9 days ago

DEADLINE

in 7 days

AI Contract Overview

The Defense Health Agency is conducting market research through a Request for Information to identify qualified offerors capable of supplying AB023, a contact activation pathway function blocking antibody targeting Coagulation Factor XI (FXI), known commercially as Xisomab 3G3 or Gruticibart. The antibody must selectively inhibit FXI activation by FXIIa within the contact pathway to prevent pathological clotting on artificial surfaces such as ECMO circuits, hemodialysis equipment, catheters, and in cancer-related thrombosis, while preserving normal hemostasis by not interfering with FXI activation by thrombin or the conversion of Factor IX by FXIa. The supplier must deliver no more than 0.5 grams of AB023 annually and provide comprehensive pharmacokinetic and pharmacodynamic data, including dose-dependent prolongation of aPTT without altering PT, alongside validation through clotting assays to confirm stability, potency, and efficacy in preventing platelet-rich thrombus and fibrin accumulation. Responses must demonstrate technical expertise and experience relevant to the functional requirements, with no reimbursement provided for submission costs. All interested parties must be registered in the System for Award Management and submit their information via email to the designated points of contact no later than June 18, 2026, at 10:00 a.m. Eastern Time. The North American Industry Classification System code is 541714 for Research and Development in Biotechnology, with a small business size standard of 1,000 employees. This RFI is strictly for market research purposes and does not obligate the Government to issue a solicitation, award a contract, or reimburse any expenses. No subcontracting opportunities are anticipated, and the place of performance is listed as San Antonio, Texas, with the contracting office located at Fort Detrick, Maryland. The announcement explicitly states that responses will not be acknowledged as a commitment to procure and are solely for evaluating industry capabilities.

General Info

Defense Health Agency seeks suppliers for AB023 antibody inhibiting FXI in medical applications, testing required.

Agency

Department Of Defense → Defense Health AgencyView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

DWG, TX, 78234, USA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed

PostedJun 12

Sources Sought

Response DeadlineJun 18

Deadline has passed

Submission Closed

06/18/2026, 02:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Defense → Defense Health Agency

Contacts2 people available

OfficeFORT DETRICK, MD, 21702, USA

Organization / Agency

Department Of Defense → Defense Health Agency

View Agency Profile

Office AddressFORT DETRICK, MD, 21702, USA

Contacts

Andy Shortall

Justin Pickett

Full Description

Request for Information Notice HT9426-26-RFI-WS03 for Contact Activation Pathway Function Blocking Antibody AB023

This is a REQUEST FOR INFORMATION (RFI) ANNOUNCEMENT ONLY. It is neither a solicitation announcement nor a request for proposals or quotes and does not obligate the Government to award a contract. Requests for a solicitation will not receive a response. Responses to this RFI must be in writing.

The purpose of this RFI announcement is to conduct market research to make appropriate acquisition decisions and to gain knowledge of potential qualified offerors interested and capable of providing the contact activation pathway function blocking antibody AB023 described below. Documentation of technical expertise must be presented in sufficient detail for the Government to determine that your company possesses the necessary functional area of expertise and experience to compete for the acquisition.

The Defense Health Agency (DHA), Defense Health Agency Contracting Activity (DHACA), 808 Schreider Street, Fort Detrick, MD 21702, is seeking potential qualified offerors to provide contact activation pathway function blocking antibody AB023:

Coagulation Factor XI (FXI) Inhibitor AB023 (Xisomab 3G3 / Gruticibart)

Shall target specific blood clotting factors without increasing the risk of bleeding
- Shall bind to the "apple 2" domain of FXI, inhibiting its activation by activated factor XII (FXIIa) in the "contact pathway" which drives clot formation in artificial surfaces
- Shall be designed for use in Extracorporeal Membrane Oxygenation (ECMO) circuits, hemodialysis, catheters, and cancer-related thrombosis
Shall preserve natural clotting (hemostasis)
- Shall not block the activation of FXI by thrombin
- Shall not block the conversion of Factor IX by activated Factor XI (FXIa), which allows it to preserve the necessary hemostatic function of FXI activation by thrombin required for normal wound healing
Shall provide a maximum of 0.5g of AB023 each year
Shall conduct pharmacokinetics (PK) testing to determine its concentration over time and pharmacodynamics (PD) analyses on the biochemical, physiological, and molecular effects of the drug
- Shall cause a dose-dependent prolongation of the activated partial thromboplastin time (aPTT), measures how long it takes for blood to clot
- Shall not affect Prothrombin Time (PT), a blood test that measures how many seconds it takes for blood to clot
- Shall be effective at preventing platelet-rich thrombus growth and fibrin accumulation in vascular thrombosis models
Shall be validated by using clotting assays to ensure stability, dose and potency

The Government is not obligated to, nor will it, pay for or reimburse any costs associated with responding to this RFI. This notice shall not be construed as a commitment by the Government to issue a solicitation or ultimately award a contract, nor does it restrict the Government to a particular acquisition approach. The Government will in no way be bound to this information if any solicitation is issued. No subcontracting opportunity is anticipated. The North American Classification System (NAICS) code for this acquisition is 541714 – Research and Development in Biotechnology (except Nanobiotechnology); (Small Business Size Standard 1,000 employees).

Notice to potential offerors: All offerors who provide goods or services to the United States Federal Government must be registered in the System for Award Management (SAM) at www.sam.gov and complete online representations and certification in SAM.

All interested parties shall submit information by email to: william.a.shortall.civ@health.mil, and justin.h.pickett.civ@health.mil to be received no later than 18 June 2026, at 10:00ET.